COST-EFFECTIVENESS OF NIVOLUMAB (NIVO) COMBINED WITH IPILIMUMAB (IPI) COMPARED WITH NIVO AND IPI MONOTHERAPIES IN THE FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN THE UNITED STATES: ANALYSIS USING 28-MONTH OVERALL SURVIVAL (OS) DATA FROM CHECKMATE 067